Beijing, China

Xiuguo Zhang

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Ningbo Team Pharmaceutical Co., Ltd. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Xiuguo Zhang

Introduction

Xiuguo Zhang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor agents. His work focuses on creating novel compounds that exhibit enhanced therapeutic properties.

Latest Patents

One of Xiuguo Zhang's notable patents is for camptothecin derivatives having anti-tumor activity. This patent discloses novel camptothecin derivatives that demonstrate excellent water solubility and stability. The compounds show good selectivity among drugs of the same category and possess a high therapeutic index. These characteristics make them promising candidates for therapeutic agents in treating tumors.

Career Highlights

Xiuguo Zhang is currently associated with Ningbo Team Pharmaceutical Co., Ltd. His work at this company has allowed him to focus on innovative drug development. With a patent portfolio that includes 1 patent, he continues to push the boundaries of pharmaceutical research.

Collaborations

Xiuguo Zhang collaborates with various professionals in the field, including his coworker Xiaoguang Lei. Their combined expertise contributes to the advancement of innovative solutions in cancer treatment.

Conclusion

Xiuguo Zhang's contributions to the field of pharmaceuticals, particularly through his patented innovations, highlight his role as a key figure in the development of effective anti-tumor agents. His work continues to inspire advancements in cancer therapy.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…